The first stop for professional medicines advice

Administering

50 results

RelevanceNewest firstOldest firstTitle
Applied filters

LMEN: Summary of antidotes to NOACs (including those currently in development) which could impact NOAC use in the future

3 February 2016NOACs offer convenient fixed dosing without need for routine coagulation monitoring and they have predictable pharmacokinetics, fewer interactions and quicker onset (and offset) of action…

In use product safety assessment report for intravenous paracetamol in paediatrics

17 July 2018In May 2010, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a safety update to healthcare professionals in the UK highlighting the risk of…

Guidance on the Pharmaceutical Issues concerning Outpatient Parenteral Antibiotic Therapy (OPAT) and other Outpatient IV Therapy Services 1st Edition January 2018

30 July 2018The development of OPAT (Outpatient Parenteral Antibiotic Therapy) services and other outpatient intravenous therapies has been rapid over recent years and there are many models…

Hypersalivation – what are the treatment alternatives to glycopyrronium and hyoscine?

1 August 2018This Medicines Q&A outlines possible alternatives to hyoscine hydrobromide and glycopyrronium in the treatment of non drug-induced hypersalivation, e.g. botulinum toxin, amitriptyline, atropine (eye drops…

Drug-induced hypersalivation – what treatment options are available?

1 August 2018This Medicines Q&A summarises published studies or case reports concerning the pharmacological treatment of drug-induced hypersalivation (drooling or sialorrhoea), particularly hypersalivation caused by clozapine. Update…

What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?

4 September 2018This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism

Can small volume intramuscular injections be given to patients taking oral anticoagulants?

17 September 2018This Medicines Q&A discusses the potential risks associated with the administration of small volume IM injections to patients taking oral anticoagulants. It has been partially…

Making best use of restricted aseptic compounding capacity

18 September 2018The NHS is experiencing considerable challenges regarding the supply of aseptically prepared injectable medicines. This communication from NPSG advises all NHS customers of commercial aseptic…

How should haem arginate (human hemin) be administered in the management of acute porphyria?

29 November 2018The recommended dose for haem arginate is 3mg/kg (to a maximum of 250mg) once daily for 4 consecutive days. It should be administered as an…

The Future of Aseptic Pharmacy Services in England: Report on Phase 1 of the NHSI Review (Feb 2019 v.2)

11 February 2019A key recommendation from Lord Carter’s report “Operational productivity and performance in English NHS acute hospitals: Unwarranted variations” is to shift the balance of activity…